Pharming Group N V Quick Ratio (PHAR) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Pharming Group N v   (NASDAQ: PHAR)

Pharming Group N V 's Quick Ratio

PHAR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 0.66 below Pharming Group N V average.

Within Major Pharmaceutical Preparations industry 316 other companies have achieved higher Quick Ratio than Pharming Group N V in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1499, from total ranking in the third quarter 2025 at 2167.

Explain Quick Ratio?
How much Cash & cash equivalents PHAR´s has?
What are PHAR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PHAR Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 57.88 % 56.89 % 56.89 % 56.89 % -6.7 %
Y / Y Cash & cash equivalent Change 164.46 % 164.46 % 164.46 % 164.46 % -11.01 %
Quick Ratio MRQ 0.66 1.25 1.25 1.25 0.39
PHAR's Total Ranking # 1499 # 2167 # # #
Seq. Current Liabilities Change 91.46 % 0 % 0 % -17.54 % 90.26 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 164.46 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 317
Healthcare Sector # 568
Overall Market # 1499


Quick Ratio Statistics
High Average Low
4.1 2.17 0.74
(Dec 31 2021)   (Dec 31 2024)




Financial Statements
Pharming Group N V 's Current Liabilities $ 222 Millions Visit PHAR's Balance sheet
Pharming Group N V 's Cash & cash equivalent $ 145 Millions Visit PHAR's Balance sheet
Source of PHAR's Sales Visit PHAR's Sales by Geography


Cumulative Pharming Group N V 's Quick Ratio

PHAR's Quick Ratio for the trailling 12 Months

PHAR Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 57.28 % 31.16 % 18.54 % 6.2 % -5.87 %
Y / Y Cash & cash equivalent TTM Growth 164.46 % 116.64 % 71.62 % 29.13 % -11.01 %
Quick Ratio TTM 1.02 1.01 0.9 0.77 0.61
Total Ranking TTM # 2980 # 3704 # # #
Seq. Current Liabilities TTM Growth 16.66 % 9.42 % 10.4 % 11.6 % -2.71 %
Seq. Cash & cash equivalent TTM Growth 18.41 % 22.56 % 29.14 % 41.12 % -3 %

Quick ratio ranking by company, industry and sector >> Back to PHAR Financial Strength Comparisons >> Go to Compare PHAR Quick Ratio to its Competitors

On the trailing twelve months basis PHAR Cash & cash equivalent more than doubled by 164.46 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Pharming Group N V 's Quick Ratio to 1.02, Quick Ratio remained below PHAR average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 372 other companies have achieved higher Quick Ratio than Pharming Group N V . While Quick Ratio overall ranking has improved so far to 2980, from total ranking during the twelve months ending third quarter 2025 at 3704.

Explain Quick Ratio?
How much Cash & cash equivalents PHAR´s has?
What are PHAR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 373
Healthcare Sector # 779
Within the Market # 2980


trailing twelve months Quick Ratio Statistics
High Average Low
4.1 2.83 0.79
(Dec 31 2021)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Amphastar Pharmaceuticals Inc   1.80 $ 285.012  Millions$ 158.156  Millions
Cns Pharmaceuticals Inc   1.76 $ 7.201  Millions$ 4.101  Millions
Vertex Pharmaceuticals Inc  1.71 $ 6,608.100  Millions$ 3,861.200  Millions
Zai Lab Limited  1.62 $ 688.358  Millions$ 424.417  Millions
Alaunos Therapeutics Inc   1.60 $ 1.385  Millions$ 0.867  Millions
Fortress Biotech Inc   1.60 $ 79.381  Millions$ 49.744  Millions
Geovax Labs Inc   1.59 $ 3.086  Millions$ 1.937  Millions
Werewolf Therapeutics Inc   1.58 $ 57.050  Millions$ 36.148  Millions
Therapeuticsmd Inc   1.56 $ 7.483  Millions$ 4.785  Millions
Rigel Pharmaceuticals Inc  1.56 $ 154.955  Millions$ 99.237  Millions
Emergent Biosolutions Inc   1.55 $ 205.400  Millions$ 132.200  Millions
60 Degrees Pharmaceuticals Inc   1.49 $ 2.751  Millions$ 1.843  Millions
Maia Biotechnology Inc   1.48 $ 8.658  Millions$ 5.836  Millions
Apellis Pharmaceuticals Inc   1.47 $ 466.233  Millions$ 316.509  Millions
Sarepta Therapeutics Inc   1.43 $ 939.650  Millions$ 656.648  Millions
Legend Biotech Corporation  1.42 $ 901.900  Millions$ 636.400  Millions
Ibio inc   1.41 $ 8.608  Millions$ 6.106  Millions
Indaptus Therapeutics Inc   1.38 $ 8.508  Millions$ 6.159  Millions
Macrogenics Inc   1.38 $ 57.217  Millions$ 41.586  Millions
Arcutis Biotherapeutics Inc   1.37 $ 178.075  Millions$ 129.838  Millions
Addex Therapeutics Ltd  1.37 $ 1.639  Millions$ 1.199  Millions
Inflarx N V  1.34 $ 19.545  Millions$ 14.540  Millions
Inovio Pharmaceuticals Inc   1.34 $ 58.512  Millions$ 43.669  Millions
Inventiva S a   1.31 $ 113.784  Millions$ 86.663  Millions
Theriva Biologics inc   1.30 $ 13.056  Millions$ 10.014  Millions
Moleculin Biotech Inc   1.30 $ 8.878  Millions$ 6.854  Millions
Uniqure N v   1.28 $ 80.240  Millions$ 62.919  Millions
Apimeds Pharmaceuticals US, Inc.  1.26 $ 13.273  Millions$ 10.545  Millions
Vireo Growth Inc.  1.25 $ 103.230  Millions$ 82.545  Millions
Vanda Pharmaceuticals Inc   1.24 $ 84.851  Millions$ 68.297  Millions

Date modified: 2026-07-07T12:47:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.